Potential Savings in the Cost of Caring for Alzheimer's Disease: Treatment with Rivastigmine

Abstract

Alzheimer's disease, Antidementias, Cost analysis, Pharmacoeconomics, Rivastigmine

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Last time updated on 14/01/2014